The outstanding metabolic stability of a 14C-labeled β-nonapeptide in rats -: in vitro and in vivo pharmacokinetic studies

被引：77

作者：

Wiegand, H

Wirz, B

Schweitzer, A

Camenisch, GP

Perez, MIR

Gross, G

Woessner, R

Voges, R

Arvidsson, PI

Frackenpohl, J

Seebach, D

机构：

[1] Swiss Fed Inst Technol, Organ Chem Lab, CH-8093 Zurich, Switzerland

[2] Novartis Pharma AG, Drug Metab & Pharmacokinet, CH-4002 Basel, Switzerland

来源：

BIOPHARMACEUTICS & DRUG DISPOSITION | 2002年 / 23卷 / 06期

关键词：

beta-peptide; ADME; rats; CaCo-2; cells; protein binding;

D O I：

10.1002/bdd.334

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In vitro studies: In CaCo-2 cell monolayers the beta-nonapeptide H(beta-HAla-beta-HLys-betaHPhe)(3)-OH . 4HCl (1), C-14-labeled on both C atoms of the CH2-CO moiety of the central beta-HPhe residue, showed a low intrinsic permeability (<1%) and is subject to a prominent efflux system. The beta-peptide (1) binds to human and rat plasma protein in vitro independent of the concentration of 1 and of the species (30-36% bound fraction at 50, 500, and 5000 ng/ml), and has only low affinity for the corresponding blood cells (less than 5% of compound 1 in blood cells). In vivo studies: The in vivo pharmacokinetic characteristics after i.v. administration of 5 mg/kg (to male rats and to bile-duct-operated rats) were: W negligible in vivo biotransformation of 1 (in urine, plasma and feces unchanged 1 represented virtually the only compound-related molecule); (ii) rapid initial decline (0-8 h post dose) of levels of compound 1 in blood and plasma followed by a slower decline (8-96 h post dose); (iii) in non-operated animals after 96 h only 38% of the dose was excreted and after 168 h 49% of the dose was found remaining in the carcass; elimination through the intestine wall represented the major elimination pathway in non-operated animals while in bile-duct-cannulated animals biliary excretion was not found to contribute substantially to elimination (iv) quantitative whole-body autoradioluminography (QWBAL) investigations revealed that the kidney was by far the most important target organ of distribution; other tissues with high concentrations of compound-related radioactivity were cartilage, lymph nodes, and liver, whereas lowest levels were found in white fat and in the brain. After p.o. administration (10 mg/kg) negligible radioactivity was observed in the systemic circulation, indicating negligible absorption; essentially the entire oral dose was recovered unchanged in feces collected over a period of 96 h. Copyright (C) 2002 John Wiley Sons, Ltd.

引用

页码：251 / +

页数：11

共 25 条

[1]

Seebach D., Overhand M., Kuhnle F.N.M., Martinoni B., Oberer L., Hommel U., Widmer H., β-Peptides: Synthesis by Arndt-Eistert homologation with concomitant peptide coupling. Structure determination by NMR and CD spectroscopy and by X-ray crystallography. Helical secondary structure of a β-Hexapeptide in solution and its stability towards pepsin, Helv. Chim. Acta, 79, pp. 913-941, (1996)

[2]

Seebach D., Abele S., Gademann K., Guichard G., Hintermann T., Jaun B., Matthews J.L., Schreiber J.V., Oberer L., Hommel U., Widmer H., β2- and β3-peptides with proteinaceous side chains: Synthesis and solution structures of constitutional isomers, a novel helical secondary structure and the influence of solvation and hydrophobic interactions on folding, Helv. Chim. Acta, 81, pp. 932-982, (1998)

[3]

Seebach D., Abele S., Gademann K., Jaun B., Pleated Sheets and Turns of β-peptides with proteinogenic side chains, Angew Chem. Int. Ed, 38, pp. 1595-1597, (1999)

[4]

Gademann K., Kimmerlin T., Hoyer D., Seebach D., Peptide folding induces high and selective affinity of a linear and small β-peptide to the human somatostatin receptor 4, J. Med. Chem, 44, (2001)

[5]

Arvidsson P.I., Rueping M., Seebach D., Design, machine synthesis, and NMR-solution structure of a β-heptapeptide forming a salt-bridge stabilised 314-helix in methanol and in water, Chem. Commun, pp. 649-650, (2001)

[6]

Hintermann T., Seebach D., The Biological Stability of β-Peptides: No interactions between α- and β-peptidic structures?, Chimia, 51, pp. 244-247, (1997)

[7]

Seebach D., Abele S., Schreiber J.V., Martinoni B., Nussbaum A.K., Schild H., Schulz H., Hennecke H., Woessner R., Bitsch F., Biological and pharmacokinetic studies with β-peptides, Chimia, 52, pp. 734-739, (1998)

[8]

Arvidsson P.J., Frackenpohl J., Ryder N.S., Liechty B., Petersen F., Zimmermann H., Camenisch C.P., Woessner R., Seebach D., On the antimicrobial and hemolytic activities of amphiphilic B-peptides, Chem. Bio. Chem, 2, pp. 771-773, (2001)

[9]

Frackenpohl J., Arvidsson P.I., Schreiber J.V., Seebach D., The outstanding biological stability of β- and γ-peptides toward proteolytic enzymes: An in vitro investigation with fifteen peptidases, Chem. Bio. Chem, 2, pp. 445-455, (2001)

[10]

Werder M., Hauser H., Abele S., Seebach D., β-Peptides as Inhibitors of small-intestinal cholesterol and fat absorption, Helv. Chim. Acta, 82, pp. 1774-1783, (1999)

← 1 2 3 →